Eko Health names cardiologist Steven Steinhubl as chief medical officer

Eko Health has appointed Steven R. Steinhubl as chief medical officer, the company announced, as the firm seeks to expand adoption of artificial intelligence-enabled tools for detecting heart and lung diseases.

The San Francisco-area company said Steinhubl also will join its executive leadership team and help direct clinical strategy, research programs and scientific partnerships aimed at accelerating the use of AI-assisted cardiac screening technologies in healthcare systems globally.

Steinhubl said the integration of high-quality physiological data with AI analytics could improve cardiovascular care by helping clinicians identify cardiac risks earlier while maintaining existing clinical workflows.

“By embedding AI into a tool clinicians already use every day, we can support earlier recognition of cardiac risk without disrupting workflow,” Steinhubl said in a statement. He added that he plans to focus on expanding the scientific foundation and clinical partnerships surrounding the company’s technology.

Steinhubl currently serves as the Vincent P. Reilly Professor of Biomedical Engineering at Purdue University in the Weldon School of Biomedical Engineering and is affiliated with the Regenstrief Center for Healthcare Engineering.

Eko said Steinhubl’s background spans engineering, physiology and medicine, with research interests that include wearable sensor technologies, machine learning in healthcare, virtual-first care delivery and digital tools designed to address health inequities. The company said he has led large-scale clinical research efforts focused on earlier detection and prevention of cardiovascular disease.

Connor Landgraf, Eko’s co-founder and chief executive officer, said Steinhubl’s experience in both clinical medicine and emerging technologies would help the company continue expanding its AI-powered cardiac detection platform.

The appointment comes during a period of growth and regulatory progress for Eko. The company said the Centers for Medicare & Medicaid Services finalized national payment for its SENSORA platform under the Outpatient Prospective Payment System.

Eko also highlighted several developments over the past year, including the addition of former U.S. Surgeon General Jerome Adams as a distinguished medical advisor and publication of results from the independently run TRICORDER study in The Lancet.

The company said it also expanded partnerships with health systems, including a deployment at Wayne General Hospital aimed at improving access to earlier cardiovascular screening in rural communities.

Internationally, Eko recently launched its AI-powered stethoscope platform in the United Kingdom and expanded into Canada after receiving Health Canada clearance for its CORE 500 Digital Stethoscope.

Eko said its FDA-cleared platform includes digital stethoscopes, electrocardiogram devices, software and AI-powered analysis tools designed to help clinicians detect and monitor heart and lung disease earlier. The company said more than 700,000 of its devices have been sold worldwide.